Novel Glucose-Responsive Insulin Formulations Using Chemically Modified Insulin Derivatives and Non-Covalent Insulin-Binding Molecules

Compounds, compositions, and methods for “smart” delivery of a therapeutic, prophylactic or diagnostic agent, such as glucose-mediated delivery of insulin through glucose-sensing insulin derivatives, are provided. The insulin derivatives bind serum albumin or agglomerate in vivo. The insulin derivatives effectively dissociate to release insulin in a hyperglycemic condition, where the complexation of glucose to a glucose-sensing element alters properties of the insulin derivative leading to the dissociation. The compounds, compositions, and methods provide a delivery strategy for both self-regulated and long-term diabetes management.

Researchers

Arturo Vegas / Yair Levi / Yunlong Zhang / Benjamin Tang / Hung-Chieh (Danny) Chou / Kun Xue / Matthew Webber / Rosemary Kanasty / Robert Langer / Daniel Anderson

Departments: Office of the Institute Professors, Department of Chemical Engineering
Technology Areas: Chemicals & Materials: Composites / Computer Science: Bioinformatics / Therapeutics: Cell Based Therapy
Impact Areas: Healthy Living

  • insulin derivatives for diabetes treatment
    United States of America | Granted | 9,867,869

License this technology

Interested in this technology? Connect with our experienced licensing team to initiate the process.

Sign up for technology updates

Sign up now to receive the latest updates on cutting-edge technologies and innovations.

More Technologies